Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4737 - Localized undifferentiated endometrial sarcomas (LUES): results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts)


11 Sep 2017


Poster display session


Gynaecological Malignancies;  Sarcoma


Marie Meurer


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


M. Meurer1, F. Duffaud2, S. Salas2, F. Bertucci3, A. Floquet4, N. Penel5, I. Ray-Coquard6, A. Italiano7, J. Blay8, P. Pautier9, M. Delannes10, S. Piperno-Neumann11, J. Mancini1, M. Auriche9

Author affiliations

  • 1 13, CHU La Timone Adultes, 13085 - Marseille/FR
  • 2 Oncology, CHU La Timone Adultes, 13385 - Marseille/FR
  • 3 13, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 4 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 5 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 6 Medical Oncology, Centre Léon Bérard, Lyon/FR
  • 7 Medicine, Institute Bergonié, 33076 - Bordeaux/FR
  • 8 Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 9 Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 10 31, IUCT, 3100 - Toulouse/FR
  • 11 Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR


Abstract 4737


UES are tumors of very bad prognosis. Although large surgical resection is the cornerstone of curative intent treatment, the optimal post-operative strategy remains unclear.


We conducted a retrospective analysis of LUES pts (Stade I-III) over the last 8 years in 10 FSG centers, from Netsarc and RRePs databases.


Thirty-nine pts with primary LUES treated from 2008 to 2016 were included, with median age of 61 years (range, 43-80), and median ECOG of 0 (range, 0-3). Metrorrhagia, abdominal pain, and pelvic mass bleeding were the most common symptoms. The locoregional extension report usually included: gynecological examination (71%), and/or pelvic MRI (83%) and/or abdomino-pelvic CT scan (43%). The remote extension report was performed preoperatively for only 17/39 (50%) pts. Among 39 LUES, 24 (67%) were stage I, 3 (8%) stage II and 9 (25%) stage III. All the patients were operated on and surgical procedures were radical hysterectomy and bilateral oophorectomy for 26/39 (70%).Tumor resections were mostly R0, 23/39 (74%) and R1, 6/39 (19%). Tumor rupture occurred in 6 pts. For 7/39 LUES there was a positivity of hormonal receptors and/or cyclin D1. Twenty-two (56%) received post-operative radiotherapy (11 of them with complementary brachytherapy) and 11 (31%) adjuvant chemotherapy. With a median follow-up of 33 months (0.3-112), 17/39 pts are alive, 21/39 (54%) relapsed (7 local relapse and 13 metastases). The 3- and 5-year Overall Survival (OS) rates are 49.8% and 31.1% respectively. Median OS and Relapse-Free Survival (RFS) are 32.7 (16.3-49.1) and 23 (4.4-41.6) months, respectively. In univariate analysis; early FIGO stage (p 


Treatment of primary LUES is radical hysterectomy and bilateral oophorectomy. Adjuvant radiotherapy appears beneficial for RFS and OS. The FIGO stage seems to have an impact on OS. A prospective study could be carried out to validate this therapeutic management.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.